SMTL ID : 7r0m.1 (1 other biounit)

KRasG12C in complex with GDP and JDQ443

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.61 Å

Oligo State

monomer

Ligands

2 x MG: MAGNESIUM ION(Non-covalent)

MG.1: 2 residues within 4Å: Chain A: S.18 Ligands: GDP.4 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:S.18, H2O.1, H2O.2, H2O.2, H2O.3 MG.2: 1 residues within 4Å: Chain A: E.64 2 PLIP interactions: 2 interactions with chain A Metal complexes: A:E.64, A:E.64

1 x H2T: 1-[6-[4-(5-chloranyl-6-methyl-1~{H}-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]propan-1-one(Covalent)

H2T.3: 19 residues within 4Å: Chain A: G.11, C.13, K.17, P.35, A.60, G.61, Q.62, E.63, E.64, Y.65, S.66, R.69, D.70, M.73, Y.97, Q.100, I.101, R.103, V.104 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:E.63, A:R.69, A:M.73, A:Q.100, A:I.101, A:V.104 Hydrogen bonds: A:K.17, A:S.66, A:D.70, A:D.70, A:R.103 Water bridges: A:Q.100

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)

GDP.4: 21 residues within 4Å: Chain A: A.12, C.13, G.14, V.15, G.16, K.17, S.18, A.19, F.29, V.30, D.31, E.32, Y.33, N.117, K.118, D.120, L.121, S.146, A.147, K.148 Ligands: MG.1 20 PLIP interactions: 20 interactions with chain A Hydrogen bonds: A:G.14, A:V.15, A:G.16, A:K.17, A:S.18, A:A.19, A:V.30, A:E.32, A:N.117, A:K.118, A:K.118, A:A.147, A:K.148 Water bridges: A:S.18, A:S.18, A:Y.33 Salt bridges: A:K.17, A:D.120 pi-Stacking: A:F.29, A:F.29

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Weiss, A. et al., Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov (2022)

Release Date

2022-04-27

Peptides

GTPase KRas: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

GTPase KRas

Related Entries With Identical Sequence